+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

LAMEA Sepsis Diagnostics Market Size, Share & Industry Trends Analysis Report By Method, By Test Type, By Pathogen, By Product, By End-User, By Technology, By Country and Growth Forecast, 2022-2028

  • PDF Icon

    Report

  • 142 Pages
  • April 2022
  • Region: Africa, Middle East
  • Marqual IT Solutions Pvt. Ltd (KBV Research)
  • ID: 5600596
The Latin America, Middle East and Africa Sepsis Diagnostics Market is expected to witness market growth of 14.0% CAGR during the forecast period (2022-2028).

Children account for a significant proportion of the total instances of sepsis diagnosed each year, leading to a considerable number of deaths annually, the majority of which might be avoided with early identification and adequate clinical therapy. Diarrheal illnesses or respiratory illnesses are frequently the cause of these deaths. Obstetric infections, such as infections after an abortion or infections after a caesarean section, are the third leading cause of maternal death.

Biosensors that monitor biological or chemical interactions are frequently used to diagnose sepsis. Biosensors are devices that produce a signal proportional to analyses concentrations in biological samples. Biosensors are made up of a variety of components, including analyses, bio receptors, signal transducers, and display panels. Biosensors can identify low signals in a range of biological fluids using a minimal number of samples. Nanotechnology-based biosensors offer a revolutionary diagnostic technique that improves biomarker sensitivity and processing speed without requiring professional abilities. Biomarkers are frequently used in sepsis management for diagnostic, monitoring, prognostic, surrogate, and stratification purposes. PCT, CRP, and Interleukin-6 are three biomarkers that have proven useful in the clinical diagnosis of sepsis.

There is a significant prevalence of sepsis in Africa. According to the African Sepsis Alliance, in Africa, at least 2 million people die from sepsis each year. In addition, these figures, however, are likely to be grossly underestimated, because sepsis is rarely identified, recognized, or recorded as a cause of death in Africa. Sepsis is the third leading cause of maternal death, contributing to 11% of all maternal fatalities. Africa is predicted to have a greater incidence of maternal deaths due to sepsis, which accounts for two-thirds of infant deaths. Moreover, sepsis is a major public health issue that affects people in this region.

In well-resourced healthcare systems, there is substantial research into techniques to improve survival. Furthermore, since its beginning, the Enduring Sepsis Campaign has succeeded in elevating the profile of sepsis by raising awareness and offering evidence-based recommendations for optimal management, education, and performance improvement.

The Brazil market dominated the LAMEA Sepsis Diagnostics Market by Country in 2021, and is expected to continue to be a dominant market till 2018; thereby, achieving a market value of $20.7 million by 2028. The Argentina market is anticipated to grow at a CAGR of 14.6% during (2022-2028). Additionally, The UAE market is expected to experience a CAGR of 13.7% during (2022-2028).

Based on Method, the market is segmented into Conventional and Automated. Based on Test Type, the market is segmented into Laboratory Tests and Point-of-Care Tests. Based on Pathogen, the market is segmented into Bacterial Sepsis, Fungal Sepsis, Viral Sepsis, and Others. Based on Product, the market is segmented into Blood Culture Media, Assays & Reagents, Instruments, and Software. Based on End-User, the market is segmented into Hospitals & specialty clinics, Pathology & Reference Laboratories, and Research Laboratories & Academic Institutes. Based on Technology, the market is segmented into Blood Culture, Immunoassays, Molecular Diagnostics, Flow Cytometry, Microfluidics, and Biomarkers. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.

The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include BioMérieux S.A., F. Hoffmann-La Roche Ltd., Becton, Dickinson and Company, Abbott Laboratories, Thermo Fisher Scientific, Inc., DiaSorin S.p.A., Bruker Corporation, Siemens Healthineers AG, Danaher Corporation, and Quidel Corporation.

The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include BioMérieux S.A., F. Hoffmann-La Roche Ltd., Becton, Dickinson and Company, Abbott Laboratories, Thermo Fisher Scientific, Inc., DiaSorin S.p.A., Bruker Corporation, Siemens Healthineers AG, Danaher Corporation, and Quidel Corporation.

Scope of the Study


Market Segments Covered in the Report:


By Method
  • Conventional
  • Automated
By Test Type
  • Laboratory Tests
  • Point-of-Care Tests
By Pathogen
  • Bacterial Sepsis
  • Fungal Sepsis
  • Viral Sepsis
  • Others
By Product
  • Blood Culture Media
  • Assays & Reagents
  • Instruments
  • Software
By End-User
  • Hospitals & specialty clinics
  • Pathology & Reference Laboratories
  • Research Laboratories & Academic Institutes
By Technology
  • Blood Culture
  • Immunoassays
  • Molecular Diagnostics
  • Flow Cytometry
  • Microfluidics
  • Biomarkers

By Country
  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA

Key Market Players


List of Companies Profiled in the Report:

  • BioMérieux S.A.
  • F. Hoffmann-La Roche Ltd.
  • Becton, Dickinson and Company
  • Abbott Laboratories
  • Thermo Fisher Scientific, Inc.
  • DiaSorin S.p.A.
  • Bruker Corporation
  • Siemens Healthineers AG
  • Danaher Corporation
  • Quidel Corporation

Unique Offerings from the Publisher

  • Exhaustive coverage
  • The highest number of Market tables and figures
  • Subscription-based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free

Table of Contents

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 LAMEA Sepsis Diagnostics Market, by Method
1.4.2 LAMEA Sepsis Diagnostics Market, by Test Type
1.4.3 LAMEA Sepsis Diagnostics Market, by Pathogen
1.4.4 LAMEA Sepsis Diagnostics Market, by Product
1.4.5 LAMEA Sepsis Diagnostics Market, by End-User
1.4.6 LAMEA Sepsis Diagnostics Market, by Technology
1.4.7 LAMEA Sepsis Diagnostics Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Product Launches and Product Expansions
3.2.3 Acquisition and Mergers
3.2.4 Approvals and Trials
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2018-2022)
3.3.2 Key Strategic Move: (Acquisitions and Mergers: 2018, Jul - 2021, Dec) Leading Players
Chapter 4. LAMEA Sepsis Diagnostics Market by Method
4.1 LAMEA Conventional Market by Country
4.2 LAMEA Automated Market by Country
Chapter 5. LAMEA Sepsis Diagnostics Market by Test Type
5.1 LAMEA Laboratory Tests Market by Country
5.2 LAMEA Point-of-Care Tests Market by Country
Chapter 6. LAMEA Sepsis Diagnostics Market by Pathogen
6.1 LAMEA Bacterial Sepsis Market by Country
6.2 LAMEA Fungal Sepsis Market by Country
6.3 LAMEA Viral Sepsis Market by Country
6.4 LAMEA Others Market by Country
Chapter 7. LAMEA Sepsis Diagnostics Market by Product
7.1 LAMEA Blood Culture Media Market by Country
7.2 LAMEA Assays & Reagents Market by Country
7.3 LAMEA Instruments Market by Country
7.4 LAMEA Software Market by Country
Chapter 8. LAMEA Sepsis Diagnostics Market by End-User
8.1 LAMEA Hospitals & specialty clinics Market by Country
8.2 LAMEA Pathology & Reference Laboratories Market by Country
8.3 LAMEA Research Laboratories & Academic Institutes Market by Country
Chapter 9. LAMEA Sepsis Diagnostics Market by Technology
9.1 LAMEA Blood Culture Market by Country
9.2 LAMEA Immunoassays Market by Country
9.3 LAMEA Molecular Diagnostics Market by Country
9.4 LAMEA Flow Cytometry Market by Country
9.5 LAMEA Microfluidics Market by Country
9.6 LAMEA Biomarkers Market by Country
Chapter 10. LAMEA Sepsis Diagnostics Market by Country
10.1 Brazil Sepsis Diagnostics Market
10.1.1 Brazil Sepsis Diagnostics Market by Method
10.1.2 Brazil Sepsis Diagnostics Market by Test Type
10.1.3 Brazil Sepsis Diagnostics Market by Pathogen
10.1.4 Brazil Sepsis Diagnostics Market by Product
10.1.5 Brazil Sepsis Diagnostics Market by End-User
10.1.6 Brazil Sepsis Diagnostics Market by Technology
10.2 Argentina Sepsis Diagnostics Market
10.2.1 Argentina Sepsis Diagnostics Market by Method
10.2.2 Argentina Sepsis Diagnostics Market by Test Type
10.2.3 Argentina Sepsis Diagnostics Market by Pathogen
10.2.4 Argentina Sepsis Diagnostics Market by Product
10.2.5 Argentina Sepsis Diagnostics Market by End-User
10.2.6 Argentina Sepsis Diagnostics Market by Technology
10.3 UAE Sepsis Diagnostics Market
10.3.1 UAE Sepsis Diagnostics Market by Method
10.3.2 UAE Sepsis Diagnostics Market by Test Type
10.3.3 UAE Sepsis Diagnostics Market by Pathogen
10.3.4 UAE Sepsis Diagnostics Market by Product
10.3.5 UAE Sepsis Diagnostics Market by End-User
10.3.6 UAE Sepsis Diagnostics Market by Technology
10.4 Saudi Arabia Sepsis Diagnostics Market
10.4.1 Saudi Arabia Sepsis Diagnostics Market by Method
10.4.2 Saudi Arabia Sepsis Diagnostics Market by Test Type
10.4.3 Saudi Arabia Sepsis Diagnostics Market by Pathogen
10.4.4 Saudi Arabia Sepsis Diagnostics Market by Product
10.4.5 Saudi Arabia Sepsis Diagnostics Market by End-User
10.4.6 Saudi Arabia Sepsis Diagnostics Market by Technology
10.5 South Africa Sepsis Diagnostics Market
10.5.1 South Africa Sepsis Diagnostics Market by Method
10.5.2 South Africa Sepsis Diagnostics Market by Test Type
10.5.3 South Africa Sepsis Diagnostics Market by Pathogen
10.5.4 South Africa Sepsis Diagnostics Market by Product
10.5.5 South Africa Sepsis Diagnostics Market by End-User
10.5.6 South Africa Sepsis Diagnostics Market by Technology
10.6 Nigeria Sepsis Diagnostics Market
10.6.1 Nigeria Sepsis Diagnostics Market by Method
10.6.2 Nigeria Sepsis Diagnostics Market by Test Type
10.6.3 Nigeria Sepsis Diagnostics Market by Pathogen
10.6.4 Nigeria Sepsis Diagnostics Market by Product
10.6.5 Nigeria Sepsis Diagnostics Market by End-User
10.6.6 Nigeria Sepsis Diagnostics Market by Technology
10.7 Rest of LAMEA Sepsis Diagnostics Market
10.7.1 Rest of LAMEA Sepsis Diagnostics Market by Method
10.7.2 Rest of LAMEA Sepsis Diagnostics Market by Test Type
10.7.3 Rest of LAMEA Sepsis Diagnostics Market by Pathogen
10.7.4 Rest of LAMEA Sepsis Diagnostics Market by Product
10.7.5 Rest of LAMEA Sepsis Diagnostics Market by End-User
10.7.6 Rest of LAMEA Sepsis Diagnostics Market by Technology
Chapter 11. Company Profiles
11.1 BioMérieux S.A.
11.1.1 Company Overview
11.1.2 Financial Analysis
11.1.3 Segmental and Regional Analysis
11.1.4 Research & Development Expenses
11.1.5 Recent strategies and developments:
11.1.5.1 Acquisition and Mergers:
11.2 F. Hoffmann-La Roche Ltd.
11.2.1 Company Overview
11.2.2 Financial Analysis
11.2.3 Segmental and Regional Analysis
11.2.4 Research & Development Expense
11.2.5 Recent strategies and developments:
11.2.5.1 Partnerships, Collaborations, and Agreements:
11.2.5.2 Approvals and Trials:
11.3 Becton, Dickinson and Company
11.3.1 Company Overview
11.3.2 Financial Analysis
11.3.3 Segmental and Regional Analysis
11.3.4 Research & Development Expense
11.3.5 Recent strategies and developments:
11.3.5.1 Product Launches and Product Expansions:
11.4 Abbott Laboratories
11.4.1 Company Overview
11.4.2 Financial Analysis
11.4.3 Segmental and Regional Analysis
11.4.4 Research & Development Expense
11.4.5 Recent strategies and developments:
11.4.5.1 Acquisition and Mergers:
11.5 Thermo Fisher Scientific, Inc.
11.5.1 Company Overview
11.5.2 Financial Analysis
11.5.3 Segmental and Regional Analysis
11.5.4 Research & Development Expense
11.5.5 Recent strategies and developments:
11.5.5.1 Partnerships, Collaborations, and Agreements:
11.5.5.2 Approvals and Trials:
11.5.5.3 Acquisition and Mergers:
11.5.6 SWOT Analysis
11.6 DiaSorin S.p.A. (Luminex Corporation)
11.6.1 Company Overview
11.6.2 Financial Analysis
11.6.3 Regional Analysis
11.6.4 Research & Development Expenses
11.6.5 Recent strategies and developments:
11.6.5.1 Acquisitions and Mergers:
11.7 Bruker Corporation
11.7.1 Company Overview
11.7.2 Financial Analysis
11.7.3 Segmental and Regional Analysis
11.7.4 Research & Development Expense
11.7.5 Recent strategies and developments:
11.7.5.1 Product Launches and Product Expansions:
11.7.5.2 Acquisition and Mergers:
11.8 Siemens Healthineers AG (Siemens AG)
11.8.1 Company Overview
11.8.2 Financial Analysis
11.8.3 Segmental and Regional Analysis
11.8.4 Research & Development Expenses
11.8.5 Recent strategies and developments:
11.8.5.1 Partnerships, Collaborations, and Agreements:
11.8.5.2 Acquisition and Mergers:
11.9 Danaher Corporation
11.9.1 Company Overview
11.9.2 Financial Analysis
11.9.3 Segmental and Regional Analysis
11.9.4 Research & Development Expense
11.10. Quidel Corporation
11.10.1 Company Overview
11.10.2 Financial Analysis
11.10.3 Regional Analysis
11.10.4 Research & Development Expense
11.10.5 Recent strategies and developments:
11.10.5.1 Acquisition and Mergers:

Companies Mentioned

  • BioMérieux S.A.
  • F. Hoffmann-La Roche Ltd.
  • Becton, Dickinson and Company
  • Abbott Laboratories
  • Thermo Fisher Scientific, Inc.
  • DiaSorin S.p.A.
  • Bruker Corporation
  • Siemens Healthineers AG
  • Danaher Corporation
  • Quidel Corporation

Methodology

Loading
LOADING...